NEWTON, Mass.--(BUSINESS WIRE)--March 30, 2006--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate-based therapeutic compounds, today announced that patient enrollment has been successfully completed in Stage l of its Simon Two-Stage designed Phase II trial for third- and fourth-line treatment of colorectal cancer patients. In this Phase II study, patients with colon cancer, which has spread despite treatment with approved therapies, are receiving DAVANAT(R) plus 5-Fluorouracil (5-FU) in monthly cycles for at least two cycles or until their disease progresses.
